Compare TRVG & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | AMRN |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | Germany | Ireland |
| Employees | 893 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.8M | 336.1M |
| IPO Year | 2015 | 1998 |
| Metric | TRVG | AMRN |
|---|---|---|
| Price | $4.65 | $16.03 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 6 | 1 |
| Target Price | $3.95 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 94.1K | 78.9K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | $1.26 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $2.59 | $12.96 |
| 52 Week High | $5.00 | $20.90 |
| Indicator | TRVG | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 67.29 | 68.54 |
| Support Level | $2.78 | $13.58 |
| Resistance Level | $4.79 | $17.00 |
| Average True Range (ATR) | 0.40 | 0.66 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 90.00 | 89.83 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.